When your antidepressant isn't working: what comes next (and why there's still hope)

You tried the medication. You gave it time. You increased the dose. And you still feel the same.

If that's your experience, you're not failing at treatment. You're experiencing something that happens to roughly one in three people with depression. It has a name: treatment-resistant depression. And while the name sounds discouraging, the reality is that there are more options available today than at any point in the history of psychiatry.

This post walks through what the treatment ladder actually looks like, step by step, so you know what's ahead and why your provider might be recommending what they're recommending.

What "Treatment-Resistant" Actually Means

Treatment-resistant depression (TRD) is formally defined as depression that hasn't responded to at least two different antidepressant medications, each given at an adequate dose for an adequate duration. The FDA and the European Medicines Agency both use this definition.

That's an important detail. "Treatment-resistant" doesn't mean "untreatable." It means the first two standard approaches didn't work, and it's time to move to strategies with stronger evidence for this specific situation.

Before climbing the ladder, though, a good provider will first rule out what's called "pseudo-resistance." This means checking whether the medication was actually taken consistently, whether the dose was truly adequate, whether enough time was given (at least 6 to 8 weeks at a therapeutic dose), and whether the diagnosis itself is correct. Conditions like bipolar disorder, thyroid disease, sleep apnea, and substance use can all mimic or worsen depression and won't respond to standard antidepressants.

Step 1: The First Antidepressant

Most people start with an SSRI like sertraline (Zoloft) or escitalopram (Lexapro), or sometimes bupropion (Wellbutrin). These are first-line because they have the best balance of effectiveness and tolerability.

In the landmark STAR*D trial, the largest real-world depression treatment study ever conducted, about one-third of patients achieved remission with their first antidepressant (citalopram). That means two-thirds did not. This isn't a failure of the medication. It reflects the biological complexity of depression.

If the first medication provides partial benefit, the dose should be optimized before moving on. If there's no response at all after an adequate trial, it's time for the next step.

Step 2: Switch or Add

When the first antidepressant doesn't work, providers generally choose between two strategies: switching to a different antidepressant or adding a second medication to the first one (augmentation).

Switching options include trying a different SSRI, moving to an SNRI like venlafaxine (Effexor) or duloxetine (Cymbalta), or trying bupropion if it wasn't the first choice. In the STAR*D trial, switching to sertraline, bupropion, or venlafaxine all produced similar remission rates of about 25 to 27%.

Augmentation means keeping the current antidepressant and adding something to boost its effect. Common augmentation strategies include adding bupropion to an SSRI (one of the most common combinations in clinical practice), adding a low-dose atypical antipsychotic, or adding psychotherapy if it hasn't been tried.

A guidelines-based approach of augmenting for partial responders and switching for non-responders was associated with a higher probability of remission and lower risk of serious adverse events compared to sequential monotherapy alone.

Step 3: Atypical Antipsychotic Augmentation

This is where many patients get nervous. "An antipsychotic? But I don't have psychosis."

The name is misleading. At the low doses used for depression augmentation, these medications act more like mood stabilizers. They're among the best-studied treatments for depression that hasn't responded to antidepressants alone.

A network meta-analysis of 65 studies with over 12,000 patients found that several atypical antipsychotics significantly improved response and remission rates when added to an antidepressant. The medications with the strongest evidence include aripiprazole (Abilify), brexpiprazole (Rexulti), quetiapine (Seroquel XR), cariprazine (Vraylar), and the olanzapine-fluoxetine combination (Symbyax).

The doses used are much lower than those for schizophrenia. For example, aripiprazole for depression augmentation typically starts at 2 to 5 mg per day, compared to 10 to 30 mg for psychotic disorders. Side effects can include weight gain, akathisia (a feeling of restlessness), and sedation, so these medications require monitoring.

Step 4: Esketamine (Spravato)

Esketamine nasal spray is the first medication specifically FDA-approved for treatment-resistant depression. It works through an entirely different mechanism than traditional antidepressants: instead of targeting serotonin or norepinephrine, it acts on the glutamate system through NMDA receptor antagonism, promoting rapid synaptic plasticity.

In a head-to-head trial published in the New England Journal of Medicine, esketamine nasal spray plus an SSRI or SNRI was compared to quetiapine augmentation. Esketamine showed higher remission rates at 8 weeks and better freedom from relapse through 32 weeks.

A meta-analysis of esketamine trials found that it likely results in a large increase in remission at 24 hours compared to placebo, with moderate-certainty evidence.

There are important practical considerations. Esketamine is only available through a restricted program (REMS). It must be administered in a certified healthcare setting under direct observation, and patients must be monitored for at least 2 hours after each dose due to risks of sedation, dissociation, and blood pressure changes. Patients cannot drive for the rest of the day after treatment. The induction phase involves twice-weekly visits for the first month, transitioning to weekly and then every-other-week maintenance.

Step 5: TMS (Transcranial Magnetic Stimulation)

TMS is a non-invasive brain stimulation technique that uses magnetic pulses to stimulate nerve cells in the prefrontal cortex. It's FDA-approved for treatment-resistant depression and does not require anesthesia or sedation.

Standard TMS involves daily sessions (typically 5 days per week) for 4 to 6 weeks. Each session lasts about 20 to 40 minutes. An accelerated protocol called theta-burst stimulation (TBS) can deliver treatment in as little as 3 minutes per session, and an intensive version (Stanford Neuromodulation Therapy) delivers multiple sessions per day over 5 days.

TMS has a favorable safety profile. The most common side effects are headache and scalp discomfort at the stimulation site, both of which are typically mild and self-limited. It does not cause the cognitive side effects associated with ECT.

Step 6: ECT (Electroconvulsive Therapy)

ECT remains the most effective treatment for severe, treatment-resistant depression. It involves brief electrical stimulation of the brain under general anesthesia, inducing a controlled seizure. Modern ECT bears little resemblance to its historical portrayal.

ECT is particularly effective for depression with psychotic features, severe suicidal ideation, catatonia, and cases where rapid response is medically necessary. Response rates in treatment-resistant depression are among the highest of any psychiatric intervention.

The main limitation is cognitive side effects, particularly short-term memory loss around the time of treatment. Modern techniques (such as right unilateral electrode placement at higher doses) have significantly reduced this risk while maintaining efficacy. Most cognitive effects are temporary, though some patients report persistent gaps in memory for events around the treatment period.

A typical course involves 2 to 3 sessions per week for 3 to 4 weeks, followed by maintenance sessions as needed.

Newer Options on the Horizon

The landscape is evolving rapidly. Auvelity (dextromethorphan/bupropion) is an FDA-approved oral medication for major depressive disorder that works through NMDA receptor modulation, similar in concept to ketamine but taken as a pill at home. Zuranolone (Zurzuvae) is FDA-approved specifically for postpartum depression and works through a completely different pathway (GABA-A receptor modulation). Psilocybin-assisted therapy is in late-stage clinical trials for treatment-resistant depression, with early results showing promise.

What About Therapy?

Psychotherapy is not a separate track from medication. It's a parallel one. Cognitive behavioral therapy (CBT) has been shown to provide significant symptomatic relief when added to antidepressants in treatment-resistant depression, even when medications alone haven't been sufficient. For many patients, the combination of medication and therapy produces better outcomes than either alone.

The Bottom Line

Treatment-resistant depression is not a dead end. It's a signal to move to the next step on a well-established ladder of increasingly effective interventions. The STAR*D trial showed that if patients stayed in treatment through up to four steps, the majority eventually achieved remission.

The hardest part is often not the treatment itself but the discouragement that comes from feeling like nothing is working. If you're in that place right now, know this: the options get more powerful as you move up the ladder, not less. The fact that the first two medications didn't work doesn't predict what the third, fourth, or fifth approach will do.

Talk to your provider about where you are on this ladder and what the next step looks like. There is almost certainly something you haven't tried yet.